As a veteran of the public relations field since the 1980s (with a niche interest in crisis communications and reputation management in corporate, government and non-profit sectors), I’ve always been intrigued by really good examples of really bad PR practice in action.
The Penn State scandal has been one in which the optics, as we say in PR, were truly dreadful. So, like slowing down for a train wreck, let’s revisit this case – but from a unique perspective. Continue reading →
You may recall seeing Dr. Robert Jarvik‘s pleasant face on your TV screen a few years ago flogging Lipitor, the biggest-selling drug on the planet at that time, earning well over $12 billion a year for Pfizer – the biggest drug company on the planet.
This partnership emerged just as the company was seeking to protect Lipitor from emerging competition by cheaper generics, and just before a U.S. Congressional investigation started looking into Jarvik’s credentials and his controversial role as paid pitchman for the cholesterol-lowering statin drug. Continue reading →